Teva Pharmaceutical Industries has withdrawn its appeal of a US district court ruling from last summer that upheld Merck & Co's compound patent on its top-selling asthma drug, Singulair (montelukast sodium), according to court documents. Merck is expected to maintain a hold on its franchise in the US until 2012.
In August, a federal judge in the US District Court for the District of New Jersey upheld the validity of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?